Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function

Biochemical Society Transactions

Volumn 44, Issue 4, 2016, Pages 1142-1149

  De Vinuesa, Amaya García ^a   Bocci, Matteo ^b   Pietras, Kristian ^b   Dijke, Peter Ten ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Activin receptor like kinase 1 (ALK1); Angiogenesis; Bone morphogenetic protein; Tumour vasculature

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ACTIVIN RECEPTOR 2; ACVRL1 PROTEIN, HUMAN; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; PF-03446962;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER THERAPY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IN VIVO STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULARIZATION;

ACTIVIN RECEPTORS, TYPE II; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ENDOTHELIAL CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 85009818989     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20160093     Document Type: Article

References (49)

1. Carmeliet, P. (2003) Angiogenesis in health and disease. Nat. Med. 9, 653-660 CrossRef PubMed.
2. Carmeliet, P. (2005) Angiogenesis in life, disease and medicine. Nature 438, 932-936 CrossRef PubMed.
3. Bergers, G. and Benjamin, L.E. (2003) Angiogenesis: Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer. 3, 401-410 CrossRef PubMed.
4. Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell 100, 57-70 CrossRef PubMed.
5. Goumans, M.-J., Liu, Z. and ten Dijke, P. (2009) TGF-β signaling in vascular biology and dysfunction. Cell. Res. 19, 116-127 CrossRef PubMed.
6. David, L, Feige, J.-J. and Bailly, S. (2009) Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev. 20, 203-212 CrossRef PubMed.
7. Cai, J., Pardali, E., Sá nchez-Duffhues, G. and ten Dijke, P. (2012) BMP signaling in vascular diseases. FEBS Lett. 586, 1993-2002 CrossRef PubMed.
8. Massagué, J. (2012) TGFβ signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616-630 CrossRef PubMed.
9. Pardali, E. and ten Dijke, P. (2012) TGFβ signaling and cardiovascular diseases. Int. J. Biol. Sci. 8, 195-213 CrossRef PubMed.
10. Seki, T., Yun, J. and Oh, S.P. (2003) Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ. Res. 93, 682-689 CrossRef PubMed.
11. Oh, S.P., Seki, T., Goss, K.A., Imamura, T., Yi, Y., Donahoe, P.K., Li, L., Miyazono, K., ten Dijke, P., Kim, S. and Li, E. (2000) Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 97, 2626-2631 CrossRef PubMed.
12. Brown, M.A., Zhao, Q., Baker, K.A., Naik, C., Chen, C., Pukac, L., Singh, M., Tsareva, T., Parice, Y., Mahoney, A. et al. (2005) Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J. Biol. Chem. 280, 25111-25118 CrossRef PubMed.
13. David, L., Mallet, C., Vailhé, B., Lamouille, S., Feige, J.-J. and Bailly, S. (2007) Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: potential roles for JNK and ERK. J. Cell Physiol. 213, 484-489 CrossRef PubMed.
14. Scharpfenecker, M., van Dinther, M., Liu, Z., van Bezooijen, R.L., Zhao, Q., Pukac, L., Löwik, C.W. and ten Dijke, P. (2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci. 120, 964-972 CrossRef PubMed.
15. Urness, L.D., Sorensen, L.K. and Li, D.Y. (2000) Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 26, 328-331 CrossRef PubMed.
16. Bhatt, R.S. and Atkins, M.B. (2014) Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors? Clin. Cancer Res. 20, 2838-2845.
17. Park, S.O., Lee, Y.J., Seki, T., Hong, K.H., Fliess, N., Jiang, Z., Park, A., Wu, X., Kaartinen, V., Roman, B.L. and Oh, S.P. (2008) ALK5- And TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 111, 633-642 CrossRef PubMed.
18. Johnson, D.W., Berg, J.N., Baldwin, M.A., Gallione, C.J., Marondel, I., Yoon, S.J., Stenzel, T.T., Speer, M., Pericak-Vance, M.A., Diamond, A. et al. (1996) Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 13, 189-195 CrossRef PubMed.
19. McAllister, K.A., Grogg, K.M., Johnson, D.W., Gallione, C.J., Baldwin, M.A., Jackson, C.E., Helmbold, E.A., Markel, D.S., McKinnon, W.C., Murrell, J. et al. (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 8, 345-351 CrossRef PubMed.
20. Lamouille, S., Mallet, C., Feige, J.-J. and Bailly, S. (2002) Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 100, 4495-4501 CrossRef PubMed.
21. Goumans, M.-J., Valdimarsdottir, G., Itoh, S., Rosendahl, A., Sideras, P. and ten Dijke, P. (2002) Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J. 21, 1743-1753 CrossRef PubMed.
22. David, L., Mallet, C., Keramidas, M., Lamande, N., Gasc, J.M., Dupuis-Girod, S., Plauchu, H., Feige, J.J. and Bailly, S. (2008) Bone morphogenetic Protein-9 is a circulating vascular quiescence factor. Circ. Res. 102, 914-922 CrossRef PubMed.
23. Suzuki, Y., Ohga, N., Morishita, Y., Hida, K., Miyazono, K. and Watabe, T. (2010) BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J. Cell Sci. 123, 1684-1692 CrossRef PubMed.
24. Cunha, S.I., Pardali, E., Thorikay, M., Anderberg, C., Hawinkels, L., Goumans, M.-J., Seehra, J., Heldin, C.H., ten Dijke, P. and Pietras, K. (2010) Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J. Exp. Med. 207, 85-100 CrossRef PubMed.
25. Larrivé e, B., Prahst, C., Gordon, E., del Toro, R., Mathivet, T., Duarte, A., Simons, M. and Eichmann, A. (2012) ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway. Dev. Cell 22, 489-500 CrossRef PubMed.
26. Aspalter, I.M., Gordon, E., Dubrac, A., Ragab, A., Narloch, J., Vizá n, P., Geudens, I., Collins, R.T., Franco, C.A., Abrahams, C.L. et al. (2015) Alk1 and Alk5 inhibition by Nrp1 controls vascular sprouting downstream of Notch. Nat. Commun. 6, 7264 CrossRef PubMed.
27. Ten Dijke, P., Goumans, M.-J. and Pardali, E. (2008) Endoglin in angiogenesis and vascular diseases. Angiogenesis 11, 79-89 CrossRef PubMed.
28. Letamendía, A., Lastres, P., Botella, L.M., Raab, U., Langa, C., Velasco, B., Attisano, L. and Bernabeu, C. (1998) Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J. Biol. Chem. 273, 33011-33019 CrossRef PubMed.
29. Bergers, G. and Hanahan, D. (2008) Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603 CrossRef PubMed.
30. Bockhorn, M., Tsuzuki, Y., Xu, L., Frilling, A., Broelsch, C.E. and Fukumura, D. (2003) Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin. Cancer Res. 9, 4221-4226 PubMed.
31. Cunha, S.I. and Pietras, K. (2011) ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 117, 6999-7006 CrossRef PubMed.
32. Hawinkels, L.J., Garćia de Vinuesa, A. and ten Dijke, P. (2013) Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy. Expert Opin. Investig. Drugs 22, 1371-1383 CrossRef PubMed.
33. Cuny, G.D., Yu, P.B., Laha, J.K., Xing, X., Liu, J.-F., Lai, C.S., Deng, D.Y., Sachidanandan, C., Bloch, K.D. and Peterson, R.T. (2008) Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg. Med. Chem. Lett. 18, 4388-4392 CrossRef PubMed.
34. Yu, P.B., Deng, D.Y., Lai, C.S., Hong, C.C., Cuny, G.D., Bouxsein, M.L., Hong, D.W., McManus, P.M., Katagiri, T., Sachidanandan, C. et al. (2008) BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat. Med. 14, 1363-1369 CrossRef PubMed.
35. Sanvitale, C.E., Kerr, G., Chaikuad, A., Ramel, M.-C., Mohedas, A.H., Reichert, S., Wang, Y., Triffitt, J.T., Cuny, G.D., Yu, P.B. et al. (2013) A new class of small molecule inhibitor of BMP signaling. PLoS ONE 8, e62721 CrossRef PubMed.
36. Goff, L.W., Cohen, R.B., Berlin, J.D., de Braud, F.G., Lyshchik, A., Noberasco, C., Bertolini, F., Carpentieri, M., Stampino, C.G., Abbattista, A. et al. (2016) A phase I study of the anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962 in patients with advanced solid tumors. Clin. Cancer Res. 22, 2146-2154 CrossRef PubMed.
37. Bendell, J.C., Gordon, M.S., Hurwitz, H.I., Jones, S.F., Mendelson, D.S., Blobe, G.C., Agarwal, N., Condon, C.H., Wilson, D., Pearsall, A.E. et al. (2014) Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin. Cancer Res. 20, 480-489 CrossRef PubMed.
38. van Meeteren, L.A., Thorikay, M., Bergqvist, S., Pardali, E., Stampino, C.G., Hu-Lowe, D., Goumans, M.J. and ten Dijke, P. (2012) Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J. Biol. Chem. 287, 18551-18561 CrossRef PubMed.
39. Ten Dijke, P., Yamashita, H., Ichijo, H., Franzé n, P., Laiho, M., Miyazono, K. and Heldin, C.H. (1994) Characterization of type I receptors for transforming growth factor-β and activin. Science 264, 101-104 CrossRef PubMed.
40. Hu-Lowe, D.D., Chen, E., Zhang, L., Watson, K.D., Mancuso, P., Lappin, P., Wickman, G., Chen, J.H., Wang, J., Jiang, X. et al. (2011) Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res. 71, 1362-1373 CrossRef PubMed.
41. Gupta, S., Gill, D., Pal, S.K. and Agarwal, N. (2015) Activin receptor inhibitors-dalantercept. Curr. Oncol Rep. 17, 14 CrossRef PubMed.
42. Mitchell, D., Pobre, E.G., Mulivor, A.W., Grinberg, A.V., Castonguay, R., Monnell, T.E., Solban, N., Ucran, J.A., Pearsall, R.S., Underwood, K.W. et al. (2010) ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol. Cancer Ther. 9, 379-388 CrossRef PubMed.
43. Hanahan, D. (1985) Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315, 115-122 CrossRef PubMed.
44. Cunha, S.I., Bocci, M., Lovrot, J., Eleftheriou, N., Roswall, P., Cordero, E., Lindström, L., Bartoschek, M., Haller, B.K., Pearsall, R.S. et al. (2015) Endothelial ALK1 is a therapeutic target to block metastatic dissemination of breast cancer. Cancer Res. 75, 2445-2456 CrossRef PubMed.
45. Hawinkels, L.J.A.C., de Vinuesa, A.G., Paauwe, M., Kruithof-de Julio, M., Wiercinska, E., Pardali, E., Mezzanotte, L., Keereweer, S., Braumuller, T.M., Heijkants, R.C. et al. (2016) Activin receptor-like kinase 1 ligand trap reduces microvascular density and improves chemotherapy efficiency to various solid tumors. Clin. Cancer Res. 22, 96-106 CrossRef PubMed.
46. Yoshimatsu, Y., Lee, Y.G., Akatsu, Y., Taguchi, L., Suzuki, H.I., Cunha, S.I., Maruyama, K., Suzuki, Y., Yamazaki, T., Katsura, A. et al. (2013) Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression. Proc. Natl. Acad. Sci. 110, 18940-18945 CrossRef.
47. Mahmoud, M., Borthwick, G.M., Hislop, A.A. and Arthur, H.M. (2009) Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH. Lab Invest. 89, 15-25 CrossRef PubMed.
48. Rosen, L.S., Hurwitz, H.I., Wong, M.K., Goldman, J., Mendelson, D.S., Figg, W.D., Spencer, S., Adams, B.J., Alvarez, D., Seon, B.K. et al. (2012) A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin. Cancer Res. 18, 4820-4829 CrossRef PubMed.
49. Makker, V., Filiaci, V.L., Chen, L.-M., Darus, C.J., Kendrick, J.E., Sutton, G., Moxley, K. and Aghajanian, C. (2015) Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N. Gynecol. Oncol. 138, 24-29 CrossRef PubMed.